Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) generates frequent news as a medical technology company focused on obstructive sleep apnea (OSA), snoring and other sleep-related breathing disorders. News about Vivos often centers on its FDA-cleared oral appliance technologies, clinical data releases, acquisitions of sleep centers and collaborations with medical practices that adopt its treatment methods.
Readers following VVOS news can expect regular updates on the company’s Complete Airway Repositioning and/or Expansion (CARE) devices, including the DNA appliance for pediatric OSA and other oral appliances in its portfolio. Vivos has announced multicenter clinical trial results, additional clinical datasets and peer-reviewed publications that it says support the safety and efficacy of its devices in both children and adults. These clinical milestones are a recurring theme in the company’s press releases.
Vivos also issues news about its business model and operations, such as the acquisition of The Sleep Center of Nevada and the rollout of an updated sleep practice affiliation model with partners like MISleep Solutions in Auburn Hills, Michigan. These items describe how Vivos integrates its diagnostic tools and therapies into sleep testing and treatment centers, and how it deploys Sleep Optimization teams to manage patient demand.
In addition, VVOS news includes financial results, conference call announcements, Medicare and CMS PDAC developments related to devices like the VidaSleep oral appliance, and participation in investor or research-focused events. For investors and observers interested in the intersection of sleep medicine, medical devices and healthcare services, the VVOS news feed offers ongoing insight into how Vivos is applying its technologies and partnerships in the OSA treatment landscape.
Vivos Therapeutics (NASDAQ: VVOS) announced significant expansions and achievements in its strategic alliance with Rebis Health Holdings. The company is extending its FDA-cleared Vivos CARE treatment for OSA into two additional Denver market facilities and plans nationwide expansion through sleep center affiliations and acquisitions.
Initial data shows a 64% acceptance rate for Vivos treatment, with patients preferring it nearly 2:1 over CPAP. The company reports average per case revenue of over $4,700 with gross margins around 70% before profit sharing with Rebis. The new business model shows potential for up to four times greater profit per case compared to their previous distribution model.
The expansion includes new locations in Highlands Ranch and Westminster, expected to be operational by April. Vivos is exploring partnerships with over 2,500 accredited sleep medicine groups nationwide, aiming to accelerate revenue growth and achieve cash flow-positive operations.
Vivos Therapeutics (NASDAQ: VVOS), a medical device and technology company focused on sleep-related breathing disorders, has announced a fireside chat scheduled for February 18, 2025, at 12:00 pm ET. CEO Kirk Huntsman will engage with Water Tower Research's senior analyst Do Kim to discuss several key topics.
The discussion will cover the company's Vivos CARE devices for treating obstructive sleep apnea (OSA) and snoring in adults, as well as moderate to severe OSA in children aged 6-17. Key points to be addressed include the company's strategic shift to a medical-based business model, efforts to establish partnerships with physician-based sleep groups, OSA market dynamics, and the positioning of Vivos CARE devices in OSA treatment.
The event will be listen-only, with a replay available for 30 days in the Investor Relations section of the Vivos website.
Vivos Therapeutics (NASDAQ: VVOS) has announced a $3.5 million registered direct offering priced at-the-market, selling 709,220 shares at $4.935 per share. The company will also issue unregistered short-term warrants in a concurrent private placement to purchase up to 709,220 shares at $4.81 per share, exercisable for two years. If fully exercised, these warrants could generate additional gross proceeds of approximately $3.4 million.
The offering is expected to close around December 24, 2024, with H.C. Wainwright & Co. serving as the exclusive placement agent. Vivos plans to use the net proceeds for working capital and general corporate purposes. The shares are being offered under a shelf registration statement, while the warrants are being issued through a private placement under Section 4(a)(2) of the Securities Act.
Vivos Therapeutics (NASDAQ: VVOS) reported strong Q3 2024 financial results with revenue increasing 17% to $3.9 million compared to Q3 2023. Gross profit reached $2.3 million with margins improving to 60%. Operating expenses decreased by 8%, marking the ninth consecutive quarter of year-over-year reductions. The company achieved significant milestones including FDA clearance for treating moderate to severe OSA in children ages 6-17 and new AMA CPT codes for their devices effective January 2024. Patient treatments increased to over 47,000 worldwide, with more than 2,000 trained dentists. The company projects achieving positive cash flow from operations by mid-2025.
Vivos Therapeutics (NASDAQ: VVOS), a medical device company focused on sleep-related breathing disorders treatment, announced its plans to release Q3 2024 financial results after market close on November 14, 2024. The company will host a conference call at 5:00 PM ET on the same day to discuss results and recent developments. Investors can access the call via phone at (800) 717-1738 (US) or (646) 307-1865 (International). A replay will be available until November 29, 2024, and a live webcast can be accessed through the company's website.
Vivos Therapeutics (NASDAQ: VVOS) has announced that the American Medical Association (AMA) has issued new CPT® medical codes for all Vivos CARE oral medical devices, effective January 1, 2025. This development is expected to facilitate coverage and reimbursement by commercial medical insurance payers for the treatment of obstructive sleep apnea (OSA) in adults and children.
Vivos Chairman and CEO, Kirk Huntsman, stated that this approval will enable a larger number of patients to access their proprietary airway remodeling technology. The company believes this, along with recent regulatory approvals and their new alliance-based marketing and distribution model, will improve their position to drive revenue growth.
The AMA's CPT® 2025 code set includes 420 overall updates, with 270 new codes, 112 deletions, and 38 revisions. This approval follows Vivos' recent Medicare coverage approval and is seen as a major step towards making OSA treatment more accessible and affordable for patients nationwide, including children ages 6 to 17.
Vivos Therapeutics (NASDAQ: VVOS), a medical device company specializing in sleep-related breathing disorders treatments, has announced a $4.3 million registered direct offering of common stock. The offering involves the sale of 1,363,812 shares at $3.15 per share, priced at-the-market under Nasdaq rules. No warrants are being issued. The offering is expected to close around September 20, 2024, with H.C. Wainwright & Co. acting as the exclusive placement agent. Vivos intends to use the net proceeds for working capital and general corporate purposes. The offering is made pursuant to a previously filed and effective shelf registration statement.
Vivos Therapeutics (NASDAQ: VVOS) has received a groundbreaking FDA 510(k) clearance for its DNA appliance to treat moderate to severe obstructive sleep apnea (OSA) and snoring in children aged 6 to 17. This is believed to be the first such clearance for an oral medical device in pediatric OSA treatment. The approval is based on a multi-site clinical trial that showed significant improvements in OSA symptoms and airway volumes.
Key findings from the study include:
- 50% reduction in sleep-related breathing disorder symptoms
- 58% decrease in snoring
- 62.7% improvement in moderate and severe AHI measurements
- 40% increase in airway volumes
Vivos aims to disrupt the pediatric OSA market, estimated at 10.1 million U.S. children, with its non-invasive, safe, and effective treatment option.
Vivos Therapeutics (NASDAQ: VVOS) reported strong Q2 2024 financial results, with revenue increasing 19% both sequentially and year-over-year to $4.1 million. The company saw operating expenses decrease by 31%, marking eight consecutive quarters of year-over-year improvement. Gross profit rose to $2.7 million, with gross margin increasing to 65%. Vivos' cost-cutting initiatives led to a significant 57% reduction in operating loss. The company anticipates achieving positive cash flow in early 2025.
Key developments include receiving regulatory approvals for Medicare reimbursement of CARE oral devices, a strategic marketing alliance with a Colorado sleep center operator, and a $7.5 million equity investment from New Seneca Partners. Vivos also reported positive results from a marketing pilot for its new distribution model, with 79% of newly diagnosed OSA patients choosing Vivos' oral appliance therapy.
Vivos Therapeutics (NASDAQ: VVOS), a leading medical device company focusing on sleep-related breathing disorders, has announced the release of its second quarter 2024 financial results after market close on August 14, 2024. The company will host a conference call at 5:00 pm ET on the same day to discuss the results and provide updates on recent achievements and developments.
Investors can access the call by dialing (800) 717-1738 (US) or (646) 307-1865 (international). A replay will be available until August 28, 2024, accessible by dialing (844) 512-2921 (US) or (412) 317-6671 (international) with passcode 1157721. A live webcast and 30-day archive will be available on the company's investor relations website.
FAQ
What is the current stock price of Vivos Therapeutics (VVOS)?
What is the market cap of Vivos Therapeutics (VVOS)?
